[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367216-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-367216-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","advances-in-epigenetic-treatment-of-adult-t-cell-leukemialymphoma-a-comprehensive-review","Advances in epigenetic treatment of adult T-cell leukemia/lymphoma - a comprehensive review","","Human T-cell lymphotropic virus type 1 (HTLV-1) infection causes adult T-cell leukemia/lymphoma (ATLL), a rare and lethal malignancy affecting mature T cells. Clinical heterogeneity and poor prognosis are compounded by resistance to conventional therapies, creating major treatment challenges. This review examines emerging epigenetic strategies for ATLL, emphasizing DNA methyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and BET inhibitors, and evaluates supporting preclinical and early clinical evidence while outlining remaining gaps and future needs.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-epigenetic-treatment-of-adult-t-cell-leukemialymphoma-a-comprehensive-review/367216/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-epigenetic-treatment-of-adult-t-cell-leukemialymphoma-a-comprehensive-review/367216.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why is adult T-cell leukemia/lymphoma (ATLL) difficult to treat?","Question",{"text":63,"@type":64},"ATLL often has a poor prognosis and shows significant drug resistance to conventional therapies, making management challenging.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which epigenetic therapy classes does the review focus on for ATLL?",{"text":68,"@type":64},"The review highlights DNA methyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and BET inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"What benefits are suggested by preclinical and early clinical data?",{"text":72,"@type":64},"The review reports modest to good efficacy signals for several epigenetic therapies, supported by preclinical and early clinical studies.",{"name":74,"@type":61,"acceptedAnswer":75},"What key challenges remain for epigenetic treatment in ATLL?",{"text":76,"@type":64},"Further research is needed to identify the best drug combinations, clarify resistance mechanisms, and minimize adverse effects before translating benefits to patients.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},367216,1790219920,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Letafati et al. Clinical Epigenetics (2025) 17:39 [https://doi.org/10.1186/s13148-025-01841-z](https://doi.org/10.1186/s13148-025-01841-z)  \nClinical Epigenetics  \n REVIEW Open Access  \nAdvances in epigenetic treatment of adult T-cell leukemia/lymphoma: a comprehensive review  \nArash Letafati 1,2, Rabeeh Mehdigholian Chaijani2, Fahime Edalat3, Nazila Eslami4, Hanieh Askari5, Farideh Askari6, Sara Shirvani7, Hamed Talebzadeh7, Mahdiyeh Tarahomi8, Nila MirKhani9, Faeze Karimi 11, Mehdi Norouzi 1,2 and Sayed-Hamidreza Mozhgani 10*  \nAbstract  \nHuman T-cell lymphotropic virus type 1 (HTLV-1) infection causes the uncommon and deadly cancer known as adult T-cell leukemia/lymphoma (ATLL), which affects mature T cells. Its clinical appearance is varied, and its prognosis is often miserable. Drug resistance to conventional therapies confers significant therapeutic challenges in the management of ATLL. This review discusses the emerging role of epigenetic medical advances in the treatment of ATLL, focusing on DNA methyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and BET inhibitors. Indeed, several classes of epigenetic therapies currently exhibit trailed efficacy in preclinical and clinical studies: DNA methyltransferase inhibitors like azacitidine and decitabine reexpression of silenced tumor suppressors; histone deacetylase inhibitors like vorinostat and romidepsin induce cell cycle arrest and apoptosis; bromodomain and extra-terminal inhibitors like JQ1 disrupt oncogenic signaling pathways. Whereas preclinical and early clinical data indicate modest to good efficacy for such treatments, significant challenges remain. Here, we discuss the current state of understanding of epigenetic dysregulation in ATLL and appraise the evidence supporting the use of these epi-drugs. However, despite the opened doors of epigenetic treatment, much more research is required with regard to showing the best combinations of drugs and their resistance mechanisms, the minimization of adverse effects, and how this hope will eventually be translated into benefit for the patient with ATLL.  \nKeywords ATLL, Epigenetic treatment, DNA methylation, Histone modification, DNMTi, HDACi, HMTi  \n*Correspondence:  \nSayed-Hamidreza Mozhgani [hamidrezamozhgani@gmail.com](hamidrezamozhgani@gmail.com)  \n1 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran  \n2 Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran  \n3 Autophagy Research Center, Shiraz University of Medical Science, Shiraz, Iran  \n4 Department of Biology, Faculty of Basic Science, Islamic Azad University of Tabriz, Tabriz, Iran  \n5 Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran  \n6 Department of Biology, Faculty of Science, Yazd University, Yazd, Iran  \n7 Department of Pharmacological and Biomolecular Science, University of Milan, Milan, Italy  \n8 Department of Biology, Faculty of Basic Science, Central Tehran Branch, Islamic Azad University, Tehran, Iran  \n9 Department of Microbiology, Faculty of Science, Karaj Branch, Islamic Azad University, Alborz, Iran  \n10 Department of Microbiology and Virology, School of Medicine, Alborz University of Medical Sciences, Alborz, Iran  \n11 Department of Medical Laboratory, Shahrood University of Medical Sciences, Shahrood, Iran  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other","cbCaimDI6xiVdg8Q","https://ap.wps.com/l/cbCaimDI6xiVdg8Q","pdf",1280095,11,"English","# Abstract\n# Introduction\n## HTLV-1 biology and transmission\n## ATLL subtypes and clinical features\n# Epigenetic therapies in ATLL\n## DNA methyltransferase inhibitors\n## Histone deacetylase inhibitors\n## Histone methyltransferase inhibitors\n## BET inhibitors\n# Evidence appraisal and future directions","[{\"question\":\"Why is adult T-cell leukemia/lymphoma (ATLL) difficult to treat?\",\"answer\":\"ATLL often has a poor prognosis and shows significant drug resistance to conventional therapies, making management challenging.\"},{\"question\":\"Which epigenetic therapy classes does the review focus on for ATLL?\",\"answer\":\"The review highlights DNA methyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and BET inhibitors.\"},{\"question\":\"What benefits are suggested by preclinical and early clinical data?\",\"answer\":\"The review reports modest to good efficacy signals for several epigenetic therapies, supported by preclinical and early clinical studies.\"},{\"question\":\"What key challenges remain for epigenetic treatment in ATLL?\",\"answer\":\"Further research is needed to identify the best drug combinations, clarify resistance mechanisms, and minimize adverse effects before translating benefits to patients.\"}]","Advances in epigenetic treatment of adult T-cell leukemia/lymphoma - a comprehensive review | PDF",1790169749,28,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c24e9bc68937911a9fc890dcb7d09976.webp",983,1305,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb022432b917a072e6d058805bbc988d.webp",982,1304,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89d21d9292dcee368c9298658454cb9d.webp",981,1303,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d37f9e94e57041f12c09257faf20cc33.webp",980,1301]